Drug Trial News

RSS

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the 450 participants into two groups.

2 Sep 2025

Dormant tumor cells targeted to reduce breast cancer relapse

A first-of-its-kind, federally funded clinical trial has shown it's possible to identify breast cancer survivors who are at higher risk of their cancer coming back due to the presence of dormant cancer cells and to effectively treat these cells with repurposed, existing drugs.

2 Sep 2025

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Triglyceride levels substantially reduced with olezarsen compared to placebo

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery (MINS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak oxygen consumption compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when given on top of individually optimized lipid-lowering therapy, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

$Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction$

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of patients with MI and mildly reduced left ventricular ejection fraction (LVEF), according to an individual patient data meta-analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Drug Trial News

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

Dormant tumor cells targeted to reduce breast cancer relapse

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Triglyceride levels substantially reduced with olezarsen compared to placebo

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Lubiprostone shows promise in slowing kidney disease progression

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Constipation drug found to slow renal function decline in CKD patients

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News